SLC-0111

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

SLC-0111 是一种磺酰胺碳酸酐酶 (CA、EC 4.2.1.1) 抑制剂，对肿瘤相关酶 hCA IX 和 hCA XII 的 IC50 分别为 45 nM 和 4.5 nM。

SLC-0111 is a sulfonamide carbonic anhydrase (CA, EC 4.2.1.1) inhibitor with IC50 of 45 nM and 4.5 nM for tumor-associated enzymes hCA IX and hCA XII; showed selective CA IX/XII inhibitory profiles, displays >20-fold and >100-fold selectivity over hCA II and hCA I, respectively; reduces tumor cell growth and increases apoptotic cell death in prostate cancer cells.Pancreatic Cancer Phase 1(In Vitro):U-104 (SLC-0111) is a potent exosome inhibitor.U-104 has low inhibition for CA I (Ki=5080 nM) and CA II (Ki=9640 nM).U-104 (50 μM; for 72 hours) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. U-104 (<50 μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells. (In Vivo):U-104 (19, 38 mg/kg; daily; for 27 days) inhibits primary tumor growth in the mice implanted orthotopically with MDA-MB-231 LM2-4Luc+ cells. U-104 (19 mg/kg; daily; for 5 days) inhibits metastases formation in the 4T1 experimental metastasis mice model.U-104 (38 mg/kg; i.p.; from 11 to 27 days) significantly delays primary tumor growth and reduces cancer stem cell population in NOD/SCID mice orthotopically implanted with MDA-MB-231 LM2-4Luc+ cells.U-104 (50 mg/kg; oral gavage; continuously for 4 days and suspended for 1 day; from 10 to 30 days) shows a significant delay in tumor growth in Balb/c mice orthotopically implanted with 4T1 cells.

U-104 (SLC-0111) is a potent exosome inhibitor. ?U-104 has low inhibition for CA I (Ki=5080 nM) and CA II (Ki=9640 nM). ?U-104 (50 μM; for 72 hours) blocks the mesenchymal phenotype in the cancer stem cells population in hypoxia condition of 4T1 cells. U-104 (<50 μM) significantly reduces migration in a dose-dependent manner in metastatic MDA-MB-231 LM2-4Luc+ cells , with cells growing as compact colonies similar to parental MDA-MB-231 cells.

U-104 (19, 38 mg/kg; daily; for 27 days) inhibits primary tumor growth in the mice implanted orthotopically with MDA-MB-231 LM2-4Luc+ cells. U-104 (19 mg/kg;? daily; for 5 days) inhibits metastases formation in the 4T1 experimental metastasis mice model. U-104 (38 mg/kg; i.p.; from 11 to 27 days) significantly delays primary tumor growth and reduces cancer stem cell population in NOD/SCID mice orthotopically implanted with MDA-MB-231 LM2-4Luc+ cells. ?U-104 (50 mg/kg; oral gavage; continuously for 4 days and suspended for 1 day; from 10 to 30 days) shows a significant delay in tumor growth in Balb/c mice orthotopically implanted with 4T1 cells.

SLC 0111 | SLC0111

Membrane Transporter/Ion Channel

Carbonic Anhydrase

CarbonicanhydraseI|CarbonicanhydraseII|CarbonicanhydraseIX|CAXII

Cancer

Pancreatic Cancer

178606-66-1

309.315

C13H12FN3O3S

>98% (HPLC)

DMSO: 30.9 mg/mL (100 mM) （ < 1 mg/ml refers to the product slightly soluble or insoluble )

FC1=CC=C(C=C1)NC(NC2=CC=C(C=C2)S(N)(=O)=O)=O

4-(3-(4-fluorophenyl)ureido)benzenesulfonamide

(-20℃)

With Ice Pack

≥ 2 years